Abstract:Background: Roux-en-Y gastric bypass (RYGB) is an effective treatment for patients with type 2 diabetes (T2D) and morbid obesity. However, T2D remission after surgery has not been adequately studied in Chinese patients with a body mass index (BMI) <30 kg/m(2).Objectives: The objective of this study was to evaluate the 3-year effect of RYGB among patients with T2D with a BMI <30 kg/m(2) and elucidate the predictors of T2D remission.Setting: Department of General Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.Methods: Sixty-six Chinese patients with T2D and a BMI 25-30 kg/m(2) were retrospectively examined for metabolic outcomes 3 years after RYGB. Remission was defined as glycated hemoglobin (HbA1C) <6.5% and no medications. Binary logistic regression analysis was used to identify preoperative parameters independently predictive of diabetes remission at 1 and 3 years post-operatively [variables: sex, age, BMI, T2D duration, plasma glucose 2 hours after meal, HbA1C, fasting C-peptide, visceral fat area, free triiodothyronine, and thyroid-stimulating hormone. There was no significant difference in fasting insulin or glucose between the remission and no remission groups.Results: Patients were a mean 50.4 +/- 11.4 years of age at baseline, and 57.6% were female. Mean T2D duration was 8.9 +/- 5.2 years, baseline HbA1C level was 8.3 +/- 1.9%, and baseline BMI was 28.2 +/- 1.2 kg/m(2) (range: 25.5-30.0). BMI was 22.5 +/- 1.8 kg/m(2) (range: 19.1-28.0) at 1 year and 23.0 +/- 1.76 kg/m(2) (range: 19.7-28.0) at 3 years. Remission was achieved in 49 patients (74.2%) at 1 year and 38 patients (57.6%) at 3 years. There was a significant reduction in medication for diabetes, hypertension, and hyperlipidemia (P < .01). Compared with patients in the no remission group, patients in the remission group had higher fasting C -peptide levels (P < .01) and free triiodothyronine levels (P = .01) at 1 year. Multiple logistic regression analysis confirmed that fasting C -peptide (odds ratio = 3.795, P = .007) and free triiodothyronine (odds ratio = 4.661, P = .019) levels were predictors of T2D remission at 1 year. No significant difference was found between the 2 groups at 3 years.Conclusions: RYGB resulted in significant clinical and biochemical improvements in Chinese patients with BMI 25-30 kg/m(2) and T2D. Appropriate patient selection (better (3-cell function) may produce better outcomes. (C) 2016 American Society for Metabolic and Bariatric Surgery. All rights reserved.

Roux-en-Y Gastric Bypass Improved Insulin Resistance Via Alteration of the Human Gut Microbiome and Alleviation of Endotoxemia

Roux-en-Y gastric bypass-induced perturbative changes in microbial communities and metabolic pathways in rats

Roux-en-Y Gastric Bypass Compared to Equivalent Diet Restriction: Mechanistic Insights into Diabetes Remission.

Roux-en-Y Gastric Bypass Improves Metabolic Conditions in Association with Increased Serum Bile Acids Level and Hepatic Farnesoid X Receptor Expression in a T2DM Rat Model.

Metabolomics Study of Roux-En-Y Gastric Bypass Surgery (rygb) to Treat Type 2 Diabetes Patients Based on Ultraperformance Liquid Chromatography-Mass Spectrometry

Roux-en-Y gastric bypass potentially improved intestinal permeability by regulating gut innate immunity in diet-induced obese mice

A specific gut microbiota signature is associated with an enhanced GLP-1 and GLP-2 secretion and improved metabolic control in patients with type 2 diabetes after metabolic Roux-en-Y gastric bypass

Roux-en-Y Gastric Bypass Surgery Suppresses Hepatic Gluconeogenesis and Increases Intestinal Gluconeogenesis in a T2DM Rat Model.

Gut microbiome modified by bariatric surgery improves insulin sensitivity and correlates with increased brown fat activity and energy expenditure

Roux-en-Y Gastric Bypass in Obese Diabetic Rats Promotes Autophagy to Improve Lipid Metabolism through mTOR/p70S6K Signaling Pathway

The Family Coriobacteriaceae is a Potential Contributor to the Beneficial Effects of Roux-en-Y Gastric Bypass on Type 2 Diabetes

Effect of Roux-en-Y Gastric Bypass Surgery on Hepatic Glucolipid Metabolism in Rats with Obesity Combined with Type 2 Diabetes Mellitus

Gut microbiota after Roux-en-Y gastric bypass and sleeve gastrectomy in a diabetic rat model: Increased diversity and associations of discriminant genera with metabolic changes

Effect of Roux-En-Y Gastric Bypass on the Remission of Type 2 Diabetes: A 3-Year Study in Chinese Patients with A Bmi < 30 Kg/M(2)

Increased Energy Expenditure and Energy Loss Through Feces Contribute to the Long-Term Outcome of Roux-en-Y Gastric Bypass in a Diet-Induced Obese Mouse Model

The human gut microbiota contributes to type-2 diabetes non-resolution 5-years after Roux-en-Y gastric bypass

Temporospatial shifts in the human gut microbiome and metabolome after gastric bypass surgery

Metabolic Effects and Safety of Roux‐en‐Y Gastric Bypass Surgery Vs. Conventional Medication in Obese Chinese Patients with Type 2 Diabetes

Analysis of long-term outcome of modified gastric bypass for type 2 diabetes mellitus in Chinese patients

Effect of Modified Roux-en-Y Gastric Bypass Surgery on GLP-1, GIP in Patients with Type 2 Diabetes Mellitus